ADE 616Alternative Names: ADE-616
Latest Information Update: 27 Aug 2015
At a glance
- Originator Adeptio Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Schizophrenia
Most Recent Events
- 27 Aug 2015 Phase-I clinical trials in Schizophrenia in United Kingdom (unspecified route)